Clinical trials: Typhoid Fever
Typhoid Fever
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
The purpose of this study is to evaluate the immunogenicity and the kinetics of the anti-Vi antibody response following secondary vaccination with the Novartis Vaccines Institute for Global Health (NVGH) Vi-CRM197 vaccine in…
- Trial name
- NCT01438996
- Testing
- NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid Fever
Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy
The goal of this project is to adapt the gold nanoparticle-based surface-enhanced Raman spectroscopy (SERS) technology to clinical application.
- Trial name
- NCT06546982
- Testing
- Surface-enhanced Raman Spectroscopy
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Aachen
Vaccine
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian
Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years after immunization.
- Trial name
- NCT04741828
- Testing
- Vi-DT Typhoid Conjugate Vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid Fever
Commercial Typhoid Tests Validation Trial
Typhoid fever (typhoid) is an enteric bacterial infection caused by Salmonella enterica serovar Typhi (Salmonella Typhi; S. Typhi).
- Trial name
- NCT04801602
- Testing
- Rapid diagnostic tests
- Where
- 2 sites in Kenya, Pakistan
- Volunteers
- 3,091 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Typhoid Fever
CVD 909 Vi Prime Boost Study
The purpose of this research study is to see if giving a typhoid vaccine by mouth (an experimental vaccine, CVD 909) before giving a vaccine shot (Typhim Vi) will result in a better immune response than giving Typhim Vi vaccine…
- Trial name
- NCT00326443
- Testing
- CVD 909, Vi Polysaccharide
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Typhoid Fever
Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children
This study evaluates whether XDR Typhoid fever in children can be effectively treated with monotherapy (meropenum alone), or a combination (meropenum and azithromycin).
- Trial name
- [XDRTYPHOID] (NCT04154722)
- Testing
- Meropenem Injection, Azithromycin Powder
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Ziauddin University
Typhoid
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later.
- Trial name
- NCT07624175
- Testing
- Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM
- Where
- Burkina Faso
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Kathleen Neuzil
Vaccine-Preventable Diseases, Typhoid Fever
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years.
- Conditions
- Vaccine-Preventable Diseases, Typhoid Fever, Cholera
- Trial name
- NCT06104345
- Testing
- Oral typhoid fever vaccine, Oral cholera vaccine
- Where
- Finland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Enteric Fever, Typhoid Fever
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
The investigators aim to compare two antibiotic treatments for enteric (typhoid) fever. Three hundred patients at Patan Hospital will be enrolled in the study.
- Trial name
- NCT01421693
- Testing
- Ceftriaxone, Gatifloxacin
- Where
- 2 sites in Nepal
- Volunteers
- 300 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Enteric Fever
Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine
A Phase 1, randomised, double-blind, placebo-controlled, parallel group study in 45 healthy participants aged 18 to 45 years inclusive.
- Trial name
- NCT04349553
- Testing
- ZH9PA and ZH9, ZH9PA
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Prokarium Ltd
Enteric Fever
Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever
1. Primary Objective: o To evaluate the efficacy of intravenous azithromycin compared with meropenem in the treatment of extensively drug-resistant (XDR) enteric fever. 2.
- Trial name
- NCT07314281
- Testing
- Azithromycin, Meropenem Injection
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Indus Hospital and Health Network
Safety Issues, Immunogenicity
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants
This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.
- Trial name
- NCT03460405
- Testing
- Vi-DT Vaccine, Vi Polysaccharide Vaccine, IPV Vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid Fever
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in healthy adult male and female travelers for whom typhoid vaccination with Vivotif is recommended, as per standard practice.
- Trial name
- NCT02391909
- Testing
- Vivotif
- Where
- United States
- Volunteers
- 855 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Typhoid Fever
Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).
- Trial name
- NCT05613205
- Testing
- TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine
- Where
- Belgium
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever
Vellore Typhoid Vaccine Impact Trial
This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
- Trial name
- VEVACT (NCT05500482)
- Testing
- Typhoid conjugate Vaccine
- Where
- India
- Volunteers
- 72,400 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
Antibody Typhoid Vaccine
Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV
Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential.
- Trial name
- NCT06921460
- Where
- Indonesia
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid Fever
Evaluation Study of DPP® Typhoid Assay
Fever management is a major problem in Low and Middle Income Countries (LMICs) where access to good quality diagnostic test is often unavailable.
- Trial name
- NCT05579821
- Testing
- Typhoid DPP assay
- Where
- Pakistan
- Volunteers
- 387 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid Fever is highly endemic and an efficacious…
- Trial name
- NCT01437267
- Testing
- Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Vi Polysaccharide (PS) vaccine
- Where
- Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningococcal Disease, Meningococcal Meningitis
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Typhoid, Yellow Fever
- Trial name
- NCT01466387
- Testing
- Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine
- Where
- 5 sites in Czechia, Germany
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid, Paratyphoid Fever
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125008
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- India
- Volunteers
- 37,673 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute